Molta C, Meyer O, Dosquet C, Montes de Oca M, Babron M C, Danon F, Kaplan C, Clémenceau S, Castellano F, Levy M
Division of Rheumatology Kaiser Permanente, Cleveland, OH.
Pediatrics. 1993 Dec;92(6):849-53.
Antiphospholipid antibodies (aPL) are noted with increased frequency in patients with systemic lupus erythematosus (SLE). The main manifestations found to be associated with aPL are arterial and venous thrombotic events, thrombocytopenia, and recurrent pregnancy loss. This study is an attempt to define the incidence of aPL in patients with childhood-onset SLE and in their relatives and to correlate their presence with clinical manifestations, and especially, to evaluate the risk of thrombosis in aPL-positive subjects.
We studied 37 unrelated patients and 107 of their first-degree relatives. VDRL, IgG and IgM anticardiolipin, and IgG antiphosphatidylethanolamine antibodies were studied in all probands during periods of clinical remission and in first-degree relatives at the time of interview. Lupus anticoagulant had only been studied in probands during an SLE flare-up.
Thirty-eight percent of probands and 19% of relatives were positive for at least one aPL, with little overlap between the different aPL studied. -No aPL-negative proband developed thrombosis. Two of the aPL-positive probands had thrombotic events before testing, and a third one showed thrombosis after testing. Only two probands had high levels of IgG aCL and showed thrombosis. The occurrence of aPL positivity in relatives was not always related to its presence in probands. None of the aPL-positive relatives had had thrombosis, but recurrent fetal loss was noted in one aPL-positive mother with SLE. Although there was a high frequency of SLE, SLE-like disease, auto-immune disorders or positive serological findings for lupus in first-degree relatives, many of these relatives did not test positive for aPL.
The high levels of IgG aCL may be considered a risk factor for thrombosis. Findings in relatives suggest a multifactorial origin for autoimmune disease and antibody production.
抗磷脂抗体(aPL)在系统性红斑狼疮(SLE)患者中出现的频率增加。已发现与aPL相关的主要表现为动脉和静脉血栓形成事件、血小板减少症以及复发性流产。本研究旨在确定儿童期发病的SLE患者及其亲属中aPL的发生率,并将其存在情况与临床表现相关联,尤其是评估aPL阳性受试者的血栓形成风险。
我们研究了37名无亲缘关系的患者及其107名一级亲属。在所有先证者临床缓解期以及一级亲属访谈时,检测了性病研究实验室玻片试验(VDRL)、IgG和IgM抗心磷脂抗体以及IgG抗磷脂酰乙醇胺抗体。仅在先证者SLE发作期间研究了狼疮抗凝物。
38%的先证者和19%的亲属至少有一种aPL呈阳性,所研究的不同aPL之间几乎没有重叠。-没有aPL阴性的先证者发生血栓形成。两名aPL阳性的先证者在检测前发生了血栓形成事件,第三名在检测后出现血栓形成。只有两名先证者IgG aCL水平高并出现血栓形成。亲属中aPL阳性的发生情况并不总是与其在先证者中的存在情况相关。没有aPL阳性的亲属发生过血栓形成,但一名患有SLE的aPL阳性母亲出现了复发性胎儿丢失。虽然一级亲属中SLE、SLE样疾病、自身免疫性疾病或狼疮血清学检查阳性的频率很高,但这些亲属中许多aPL检测并未呈阳性。
高IgG aCL水平可被视为血栓形成的危险因素。亲属中的研究结果提示自身免疫性疾病和抗体产生的多因素起源。